Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
50 hedge funds and large institutions have $52.7M invested in Sio Gene Therapies Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
57% more capital invested
Capital invested by funds: $33.7M → $52.7M (+$19.1M)
25% more funds holding
Funds holding: 40 → 50 (+10)
25% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $1.66M
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.73M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$2.89M |
| 3 |
Two Sigma Investments
New York
|
+$847K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$578K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.63M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.75M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.33M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$1.38M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.16M |
SIOX Hedge Fund Activity: Q3 2020 in Review
50 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2020, worth a combined $52.7M — up 57% from $33.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SIOX positions and 5 closed out — a net gain of 10 holders — while 9 added to existing stakes and 14 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $6.73M. The largest seller was Sphera Funds Management, cutting an estimated $5.63M.
- 50 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2020, up from 40 in Q2 2020.
- Funds reported $52.7M of Sio Gene Therapies Inc. Common Stock stock for Q3 2020, up 57% quarter-over-quarter.
- 15 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2020 and 5 closed out, a net change of +10 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2020 was Opaleye Management, an estimated $6.73M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2020 was Sphera Funds Management, an estimated $5.63M sold.
Based on aggregated 13F filings for Q3 2020.